An Insider at Hims & Hers Just Filed. Here's What It Says About Buying the Dip
Soleil Boughton retains roughly 339,000 shares and additional derivative securities.
Overview
Soleil Boughton, the chief legal officer of Hims & Hers Health, Inc. (NYSE:HIMS), reported a non-discretionary disposition of 21,500 shares on August 14, according to a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($28.15); post-transaction value based on the August 14 market close ($28.15).
Details
Hims & Hers Health operates as a leading digital health platform with a $6.4 billion market capitalization and $2.6 billion in TTM revenue, positioning itself at the intersection of telehealth and direct-to-consumer pharmaceutical distribution. The company's integrated platform model creates competitive advantages through operational efficiency, customer convenience, and data-driven personalization. Despite current net losses of $142.0 million TTM, the company's substantial revenue base and market scale reflect strong consumer adoption of its digital-first healthcare delivery model.
Source
Originally published at www.fool.com.